Monitor for actual sales under the ATM program; any announcement of shares sold will pressure the stock. Watch for potential further capital raises or debt restructuring given the going-concern risk.
Price Chart
Executive Summary
RedHill Biopharma filed a prospectus supplement to increase its ATM offering by up to $2,128,000, adding further dilution risk for existing shareholders. This capital raise comes amid a going-concern warning and a $4.1M cash balance as of the 20-F filing, underscoring urgent funding needs.
Key Facts
- Filed prospectus supplement on June 29, 2026 to increase ATM offering to up to $2,128,000
- Offering is under existing ATM agreement with H.C. Wainwright & Co. dated February 3, 2025
- Company reported substantial doubt about going concern in recent 20-F (only $4.1M cash as of year-end 2025)
- Market cap is approximately $5M, making potential dilution material
Financial Impact
Up to $2,128,000 in additional capital raise, representing ~43% of market cap at current prices, leading to significant dilution for existing shareholders
Risk Factors
- Potential additional dilution as ATM shares are sold
- Insufficient cash runway without further financing
- Nasdaq delisting risk if share price remains low
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-003351 |
| Exhibit: exhibit_5-1.htm | 0001178913-26-003351 |
| Exhibit: exhibit_5-2.htm | 0001178913-26-003351 |
| Document: 0001178913-26-003351-index-headers.html | 0001178913-26-003351 |
| Document: 0001178913-26-003351-index.html | 0001178913-26-003351 |
| Document: 0001178913-26-003351.txt | 0001178913-26-003351 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.4550 | awaiting T+60 | — | $0.4230 (−7.03%) |
Oct 19, 2026 7d ago | 6-K | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 19, 2026 7d ago | Press Release | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 13, 2026 12d ago | 6-K | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 13, 2026 12d ago | 424B5 | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 7, 2026 19d ago | 6-K | $0.4740 | awaiting T+60 | — | $0.4230 (−10.76%) |
Sep 1, 2026 7w ago | 6-K | $0.8700 | awaiting T+60 | — | $0.4230 (−51.38%) |
Aug 31, 2026 8w ago | 6-K | $0.9000 | awaiting T+60 | — | $0.4230 (−53.00%) |
Aug 7, 2026 11w ago | 6-K | $0.6050 | awaiting T+60 | — | $0.4230 (−30.08%) |
Aug 6, 2026 11w ago | 6-K | $0.5810 | awaiting T+60 | — | $0.4230 (−27.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers